LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease

Free Radical Research

Volumn 49, Issue 5, 2015, Pages 681-691

  Tyurina, Y Y ^a   Polimova, A M ^a,d   Maciel, E ^c   Tyurin, V A ^a   Kapralova, V I ^a   Winnica, D E ^a   Vikulina, A S ^a,d   Domingues, M R M ^c   McCoy, J ^b   Sanders, L H ^b   Bayir, H ^a,b   Greenamyre, J T ^b   Kagan, V E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d LOMONOSOV MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Cardiolipin; Oxygenated cardiolipin species; Oxygenated linoleic acid; Parkinson's disease

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; CARDIOLIPIN; DOCOSAHEXAENOIC ACID; FATTY ACID; LINOLEIC ACID; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; ROTENONE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRADYKINESIA; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; FATTY ACID OXIDATION; LIPIDOMICS; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; MOLECULE; NONHUMAN; OXIDATIVE STRESS; OXYGENATION; PARKINSON DISEASE; PATHOGENESIS; PLASMA; PROTEIN BLOOD LEVEL; RAT; SUBSTANTIA NIGRA; ANIMAL; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEWIS RAT; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PARKINSONISM; TIME FACTOR;

ANIMALIA; RATTUS;

ANIMALS; ARACHIDONIC ACID; BIOMARKERS; CARDIOLIPINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; LINOLEIC ACID; MALE; MASS SPECTROMETRY; MITOCHONDRIA; OXIDATION-REDUCTION; PARKINSONIAN DISORDERS; RATS, INBRED LEW; ROTENONE; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 84929152086     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2015.1005085     Document Type: Article

References (65)

1. Sanders LH, Greenamyre JT. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Bio Med 2013; 62: 111-120.
2. Yao Z, Wood NW. Cell death pathways in Parkinson's disease: role of mitochondria. Antioxid Redox Signal 2009; 11: 2135-2149.
3. Sherer TB, Greenamyre JT. Oxidative damage in Parkinson's disease. Antioxid Redox Signal 2005; 7: 627-629.
4. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996; 220: 195-198.
5. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600-609.
6. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinson's Dis 2013; 3: 461-491.
7. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-827.
8. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142: 128-130.
9. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998; 57: 338-342.
10. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69: 1196-1203.
11. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381-389.
12. Kagan VE. Lipid Peroxidation in Biomembranes. Boca Raton, Florida: CRC Press; 1988.
13. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996; 93: 2696-2701.
14. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010; 345: 91-104.
15. Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA, et al. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 2005; 1: 223-232.
16. Kagan VE, Chu CT, Tyurina YY, Cheikhi A, Bayir H. Cardiolipin asymmetry, oxidation and signaling. Chem Phys Lipids 2014; 179: 64-69.
17. Tyurina YY, Domingues RM, Tyurin VA, Maciel E, Domingues P, Amoscato AA, et al. Characterization of cardiolipins and their oxidation products by LC-MS analysis. Chem Phys Lipids 2014; 179: 3-10.
18. Tyurina YY, Poloyac SM, Tyurin VA, Kapralov AA, Jiang J, Anthonymuthu TS, et al. A mitochondrial pathway for biosynthesis of lipid mediators. Nat Chem 2014; 6: 542-552.
19. Samhan-Arias AK, Ji J, Demidova OM, Sparvero LJ, Feng W, Tyurin V, et al. Oxidized phospholipids as biomarkers of tissue and cell damage with a focus on cardiolipin. Biochim Biophysica Acta 2012; 1818: 2413-2423.
20. Tyurina YY, Winnica DE, Kapralova VI, Kapralov AA, Tyurin VA, Kagan VE. LC/MS characterization of rotenone induced cardiolipin oxidation in human lymphocytes: implications for mitochondrial dysfunction associated with Parkinson's disease. Mol Nutrition Food Res 2013; 57: 1410-1422.
21. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre T. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 2005; 280: 42026-42035.
22. Sanders LH, McCoy J, Hu X, Mastroberardino PG, Dickinson BC, Chang CJ, et al. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol Dis 2014; 70: 214-223.
23. Sanders LH, Howlett EH, McCoy J, Greenamyre JT. Mitochondrial DNA damage as a peripheral biomarker for mitochondrial toxin exposure in rats. Toxicol Sci 2014; 142: 395-402.
24. Martinez TN, Greenamyre JT. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal 2012; 16: 920-934.
25. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci 2010; 31: 141-142.
26. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
27. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
28. Boettcher C, Pries C, Vangent CM. A rapid and sensitive sub-micro phosphorus determination. Anal Chim Acta 1961; 24: 203.
29. Tyurina YY, Tyurin VA, Kapralova VI, Wasserloos K, Mosher M, Epperly MW, et al. Oxidative lipidomics of gamma-radiation- induced lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Radiat Res 2011; 175: 610-621.
30. Rouser G, Fkeischer S, Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-496.
31. Sparagna GC, Johnson CA, McCune SA, Moore RL, Murphy RC. Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry. J Lipid Res 2005; 46: 1196-1204.
32. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005; 2: 484-494.
33. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. BioEssays 2002; 24: 308-318.
34. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. IUBMB Life 2001; 52: 135-141.
35. Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 2005; 134: 109-118.
36. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-164.
37. Aldrovandi M, O'Donnell VB. Oxidized PLs and vascular inflammation. Curr Atheroscler Rep 2013; 15: 323.
38. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010; 12: 1009-1059.
39. Ashraf MZ, Kar NS, Podrez EA. Oxidized phospholipids: biomarker for cardiovascular diseases. Int J Biochem Cell Biol 2009; 41: 1241-1244.
40. Schlame M, Ren M. The role of cardiolipin in the structural organization of mitochondrial membranes. Biochim Biophys Acta 2009; 1788: 2080-2083.
41. Daum G, Lees ND, Bard M, Dickson R. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 1998; 14: 1471-1510.
42. Fry M, Green DE. Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J Biol Chem 1981; 256: 1874-1880.
43. Sharpley MS, Shannon RJ, Draghi F, Hirst J. Interactions between phospholipids and NADH:ubiquinone oxidoreductase (complex I) from bovine mitochondria. Biochemistry 2006; 45: 241-248.
44. Robinson NC. Functional binding of cardiolipin to cytochrome c oxidase. J Bioenerg Biomembr 1993; 25: 153-163.
45. Eble KS, Coleman WB, Hantgan RR, Cunningham CC. Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance spectroscopy. J Biol Chem 1990; 265: 19434-19440.
46. Bayir H, Tyurin VA, Tyurina YY, Viner R, Ritov V, Amoscato AA, et al. Selective early cardiolipin peroxidation after traumatic brain injury: an oxidative lipidomics analysis. Annals Neurol 2007; 62: 154-169.
47. Ji J, Kline AE, Amoscato A, Samhan-Arias AK, Sparvero LJ, Tyurin VA, et al. Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury. Nature Neuroscience 2012; 15: 1407-1413.
48. Tyurina YY, Tyurin VA, Kaynar AM, Kapralova VI, Wasserloos K, Li J, et al. Oxidative lipidomics of hyperoxic acute lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Am J Physiol Lung Cell Mol Physiol 2010; 299: L73-85.
49. Tyurina YY, Kisin ER, Murray A, Tyurin VA, Kapralova VI, Sparvero LJ, et al. Global phospholipidomics analysis reveals selective pulmonary peroxidation profiles upon inhalation of single-walled carbon nanotubes. ACS Nano 2011; 5: 7342-7353.
50. Tyurina YY, Tyurin VA, Epperly MW, Greenberger JS, Kagan VE. Oxidative lipidomics of gamma-irradiation-induced intestinal injury. Free Radic Biology Med 2008; 44: 299-314.
51. Kiebish MA, Han X, Seyfried TN. Examination of the brain mitochondrial lipidome using shotgun lipidomics. Methods Mol Biol 2009; 579: 3-18.
52. Murphy MP. How mitochondria produce reactive oxygen species. Biochemical J 2009; 417: 1-13.
53. Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochim Biophysica Acta 2014; 1837: 408-417.
54. Bogdanov M, Mileykovskaya E, Dowhan W. Lipids in the assembly of membrane proteins and organization of protein supercomplexes: implications for lipid-linked disorders. Subcell Biochem 2008; 49: 197-239.
55. Celardo I, Martins LM, Gandhi S. Unravelling mitochondrial pathways to Parkinson's disease. Br J Pharmacol 2014; 171: 1943-1957.
56. Palikaras K, Tavernarakis N. Mitophagy in neurodegeneration and aging. Front Genet 2012; 3: 297.
57. Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimer's Dis 2014; 42: S125-152.
58. Chu CT, Ji J, Dagda RK, Jiang JF, Tyurina YY, Kapralov AA, et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat Cell Biology 2013; 15: 1197-1205.
59. Coffa G, Brash AR. A single active site residue directs oxygenation stereospecificity in lipoxygenases: stereocontrol is linked to the position of oxygenation. Proc Natl Acad Sci USA 2004; 101: 15579-15584.
60. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006; 38: 752-754.
61. Lu CS, Lai SC, Wu RM, Weng YH, Huang CL, Chen RS, et al. PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 183-191.
62. Kauther KM, Hoft C, Rissling I, Oertel WH, Moller JC. The PLA2G6 gene in early-onset Parkinson's disease. Mov Disord 2011; 26: 2415-2417.
63. Jaburek M, Jezek J, Zelenka J, Jezek P. Antioxidant activity by a synergy of redox-sensitive mitochondrial phospholipase A2 and uncoupling protein-2 in lung and spleen. Int J Biochem Cell Biol 2013; 45: 816-825.
64. Rauckhorst AJ, Broekemeier KM, Pfeiffer DR. Regulation of the Ca(2+)-independent phospholipase A2 in liver mitochondria by changes in the energetic state. J Lipid Res 2014; 55: 826-836.
65. Maeda A, Fadeel B. Mitochondria released by cells undergoing TNF-alpha-induced necroptosis act as danger signals. Cell Death Dis 2014; 5: e1312.